An in-depth analysis of the percentage of adults, especially older adults, who have glaucoma and experience vision limits due to it shows higher prevalence and disparities.

The population of older adults living with dementia is expected to swell to nearly 14 million by 2050 and is estimated to cost the US economy more than 500 billion each year. In the absence of a cure for Alzheimer's disease, the primary cause of dementia, there's interest in understanding modifiable risk factors. In theory, getting a handle on the modifiable risk factors for dementia, would enable public health efforts to reduce cognitive decline in dementia at the population level. We've come a long way in understanding the risk factors for Alzheimer's disease and other related dementias. However, there's still work to be done. In this episode, we'll speak with Dr. Josh Ehrlich, a researcher at the University of Michigan, who has examined vision impairment as a risk factor for dementia.

When a father and his two kids developed an array of peculiar symptoms, doctors, Brazilian researchers and the NIH partnered to find a diagnosis and path to treatment.

Michigan Medicine ophthalmologists create a scalable algorithm for triaging appointments during the pandemic

Kellogg Eye Center ophthalmologists explain which vitamins and supplements are actually good for your eyes.

Now with recreational marijuana legalized in Michigan, it’s easier for glaucoma patients to substitute traditional treatment methods for a joint. But does it..

One of the lesser-known consequences of osteogenesis imperfecta – brittle bone disease – is an increased risk of eye diseases like glaucoma. Patients of all ages should receive annual ophthalmic screenings.

A popular type of data collection is helping Kellogg providers make visits more meaningful for patients and reduce wait times.

Learn about the XEN Gel Stent, a minimally invasive glaucoma treatment now offered by The University of Michigan Kellogg Eye Center.

Ophthalmologist sets sights on underserved populations

Supporting research to advance treatment and prevention of the world's second-leading cause of blindness